HIF1A and neoplasm: As hypoxia, and thus HIF-1, leads to resistance to radiotherapy and chemotherapy in solid tumours [5–8], targeting HIF-1 could be an attractive treatment strategy, with the potential for disrupting multiple pathways crucial for tumour growth.